Seven coronavirus vaccines are in the final stages of testing around the world, and four of them are from China.
By:
Reuters
–
–
Sinovac Biotech Ltd.’s CoronaVac coronavirus candidate vaccine has been approved for use in emergencies as part of a program in China to vaccinate high-risk groups such as healthcare workers, a source familiar with the matter said.
China National Biotec Group (CNBG), a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), has also obtained approval for emergency use of a candidate vaccine against covid-19, the group said on WeChat social media in the past. Sunday.
CNBG, which has two candidate vaccines in phase 3 clinical trials, did not say which of its vaccines had been approved for emergency use.
China has been administering experimental coronavirus vaccines to high-risk groups since July, and a health authority told state media in an interview aired last week that authorities may consider modestly expanding the emergency use program to try to prevent possible outbreaks during fall and winter.
Officially, China has given few details about which candidate vaccines have been given to high-risk people under the program or how many have been vaccinated.
In June, before the emergency use program, employees of state-owned companies traveling abroad were allowed to receive one of two vaccines being developed by CNBG, according to state media Global Times. The Chinese military also approved the use of CanSino Biologics’ vaccine.
Seven coronavirus vaccines are in the final stages of testing around the world, and four of them are from China.
However, no vaccine has yet passed the final phase of trials that demonstrate its safety and efficacy, conditions that are normally required to obtain regulatory approval for widespread use. The coronavirus has killed more than 800,000 people around the world.
– .
